Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Inflammatory Breast Neoplasms 1Glioblastoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 100130-nm albumin-bound paclitaxel 34Oxaliplatin 28Capecitabine 27Fluorouracil 25Albumin-Bound Paclitaxel 23Leucovorin 19Irinotecan 18Erlotinib Hydrochloride 14Cyclophosphamide 12Radiosurgery 11pembrolizumab 10Radiotherapy 10Nivolumab 10Bevacizumab 10Surgical Procedures, Operative 9avelumab 7Docetaxel 7Taxes 6Cisplatin 6ruxolitinib 5folfirinox 5Specimen Handling 5Paclitaxel 5Everolimus 5Cetuximab 5ALT-803 5trametinib 4spartalizumab 4fludarabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Pancreatic Neoplasms × bemcentinib × Clear all
NCT03649321 2023-11-09

Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer

University of Texas Southwestern Medical Center

Phase 1/2 Terminated
9 enrolled 12 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡